IRIS publication 280546172
Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids
RIS format for Endnote and similar
TY - JOUR - Bernstein, C. N.,Kolodny, M.,Block, E.,Shanahan, F. - 1993 - April - Am J Gastroenterolam J Gastroenterol - Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids - Validated - () - 88 - 44 - 574 - 7 - Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose.Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose. - 0002-9270 (Print) 0002-92 DA - 1993/04 ER -
BIBTeX format for JabRef and similar
@article{V280546172, = {Bernstein, C. N. and Kolodny, M. and Block, E. and Shanahan, F. }, = {1993}, = {April}, = {Am J Gastroenterolam J Gastroenterol}, = {Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids}, = {Validated}, = {()}, = {88}, = {44}, pages = {574--7}, = {{Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose.Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose.}}, issn = {0002-9270 (Print) 0002-92}, source = {IRIS} }
Data as stored in IRIS
AUTHORS | Bernstein, C. N.,Kolodny, M.,Block, E.,Shanahan, F. | ||
YEAR | 1993 | ||
MONTH | April | ||
JOURNAL_CODE | Am J Gastroenterolam J Gastroenterol | ||
TITLE | Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids | ||
STATUS | Validated | ||
TIMES_CITED | () | ||
SEARCH_KEYWORD | |||
VOLUME | 88 | ||
ISSUE | 44 | ||
START_PAGE | 574 | ||
END_PAGE | 7 | ||
ABSTRACT | Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose.Today, Pneumocystis carinii pneumonia (PCP) is typically associated with AIDS. However, in the pre-AIDS era, PCP was known to be associated with various immunodeficiency states, malignancies, and immunosuppressive therapy, particularly the use of corticosteroids. PCP has been reported to occur during immuno-suppressive therapy of some chronic inflammatory states, but it has never been reported in patients with inflammatory bowel disease. We report two patients with ulcerative colitis who developed PCP during high-dose corticosteroid therapy, and review the literature regarding non-AIDS PCP. PCP should thus be added to the list of bronchopulmonary complications in inflammatory bowel disease. This report should give gastroenterologists further impetus to limit immunosuppressive therapy to its minimal effective dose. | ||
PUBLISHER_LOCATION | |||
ISBN_ISSN | 0002-9270 (Print) 0002-92 | ||
EDITION | |||
URL | |||
DOI_LINK | |||
FUNDING_BODY | |||
GRANT_DETAILS |